Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa

Molecular Genetics and Metabolism

Volumn 98, Issue 3, 2009, Pages 319-321

  Lipinski, Shawn E ^a   Lipinski, Michael J ^a   Burnette, Autumn ^a   Platts Mills, Thomas A ^a   Wilson, William G ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Allergy; Anaphylaxis; Enzyme replacement therapy; Lysosomal storage disease; Pompe disease

Indexed keywords

DIPHENHYDRAMINE; FAMOTIDINE; METHYLPREDNISOLONE SODIUM SUCCINATE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SALBUTAMOL;

ADULT; ANAMNESIS; ANAPHYLAXIS; ARTICLE; CASE REPORT; CHEST TIGHTNESS; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INFUSION; ELECTROMYOGRAPHY; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HOT FLUSH; HUMAN; HUMAN TISSUE; MUSCLE BIOPSY; PRICK TEST; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SKIN BIOPSY; SKIN TEST; TREATMENT OUTCOME; URTICARIA;

ADULT; ALPHA-GLUCOSIDASES; ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; TREATMENT OUTCOME;

EID: 70349733015     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.07.001     Document Type: Article

References (4)

1. Hagemans M.L., Winkel L.P., Van Doorn P.A., Hop W.J., Loonen M.C., Reuser A.J., and Van der Ploeg A.T. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 128 (2005) 671-677
2. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., De la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., and Wraith J.E. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68 (2007) 99-109
3. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., Arnold G.L., Pivnick E.K., Ottinger C.J., Robinson P.H., Loo J.C., Smitka M., Jardine P., Tato L., Chabrol B., McCandless S., Kimura S., Mehta L., Bali D., Skrinar A., Morgan C., Rangachari L., Corzo D., and Kishnani P.S. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 11 (2009) 210-219
4. Okumiya T., Kroos M.A., Vliet L.V., Takeuchi H., Van der Ploeg A.T., and Reuser A.J. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol. Genet. Metab. 90 (2007) 49-57